You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Current Therapeutic Advances Targeting EGFR and EGFRvIII in Glioblastoma
|
|---|---|
| Published in |
Frontiers in oncology, January 2015
|
| DOI | 10.3389/fonc.2015.00005 |
| Pubmed ID | |
| Authors |
Emily Padfield, Hayley P. Ellis, Kathreena M. Kurian |
| Abstract |
Epidermal growth factor receptor (EGFR) and EGFRvIII analysis is of current interest in glioblastoma - the most common malignant primary CNS tumor, because of new EGFRvIII vaccine trials underway. EGFR activation in glioblastoma promotes cellular proliferation via activation of MAPK and PI3K-Akt pathways, and EGFRvIII is the most common variant, leading to constitutively active EGFR. This review explains EGFR and EGFRvIII signaling in GBM; describes targeted therapy approaches to date including tyrosine kinase inhibitor, antibody-based therapies, vaccines and pre-clinical RNA-based therapies, and discusses the difficulties encountered with these approaches including pathway redundancy and intratumoral heterogeneity. |
X Demographics
The data shown below were collected from the profiles of 23 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 5 | 22% |
| Turkey | 2 | 9% |
| India | 2 | 9% |
| Spain | 1 | 4% |
| Switzerland | 1 | 4% |
| Malaysia | 1 | 4% |
| Unknown | 11 | 48% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 12 | 52% |
| Practitioners (doctors, other healthcare professionals) | 5 | 22% |
| Scientists | 5 | 22% |
| Science communicators (journalists, bloggers, editors) | 1 | 4% |
Mendeley readers
The data shown below were compiled from readership statistics for 274 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 3 | 1% |
| Brazil | 2 | <1% |
| Japan | 1 | <1% |
| Unknown | 268 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 52 | 19% |
| Researcher | 42 | 15% |
| Student > Bachelor | 40 | 15% |
| Student > Master | 39 | 14% |
| Other | 15 | 5% |
| Other | 48 | 18% |
| Unknown | 38 | 14% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 64 | 23% |
| Agricultural and Biological Sciences | 53 | 19% |
| Medicine and Dentistry | 52 | 19% |
| Immunology and Microbiology | 12 | 4% |
| Neuroscience | 12 | 4% |
| Other | 36 | 13% |
| Unknown | 45 | 16% |
Attention Score in Context
This research output has an Altmetric Attention Score of 17. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 August 2019.
All research outputs
#2,189,392
of 25,394,764 outputs
Outputs from Frontiers in oncology
#488
of 22,440 outputs
Outputs of similar age
#30,034
of 361,787 outputs
Outputs of similar age from Frontiers in oncology
#5
of 92 outputs
Altmetric has tracked 25,394,764 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 91st percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 22,440 research outputs from this source. They receive a mean Attention Score of 3.0. This one has done particularly well, scoring higher than 97% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 361,787 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 91% of its contemporaries.
We're also able to compare this research output to 92 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 94% of its contemporaries.